Lv1
64 积分 2025-09-23 加入
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model-Based Assessments
20天前
已完结
CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
22天前
已完结
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
22天前
已完结
The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy
1个月前
已完结
First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers
1个月前
已完结
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial
1个月前
已完结
Fratricide-resistant CD7-CAR T cells in T-ALL
1个月前
已完结
A brave new framework for glioma drug development
1个月前
已完结
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies
1个月前
已完结
皖公网安备34019202002308
